Longeveron shared its third-quarter results and plans to meet with the FDA about its HLHS program.

Nov 12, 2026, 5:14 PM ETResultsRead the original at SEC EDGAR

Bad for LGVN

Longeveron’s trial missed its main goal, though a secondary measure showed 8 major heart events with standard care and 1 with treatment. Cash conservation and an uncertain search for funding or a buyer add concern.

LGVN · Longeveron Inc.

AI read · Bad for LGVN

The AI's read

Missing the trial’s main goal weakens the case for advancing its treatment for a rare heart defect. A secondary measure showed fewer major heart events with treatment, but that does not erase the missed main goal. The company is conserving cash and reviewing funding, a sale, or a merger. No outcome is assured, adding uncertainty to its path.

Get alerts for LGVN

Follow Longeveron Inc. (LGVN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LGVN

Free on the App Store and Google Play, or on the web.